Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 4/20 | 0.54 |
| ▸ | CCR4 | P51679 | 1/20 | 0.52 |
| ▸ | EDNRB | P24530 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22088467 | 0.82 | EDNRA (0.56) | EDNRACCR4EDNRBGAALMNA | |
| SCHEMBL8390507 | 0.79 | EDNRA (0.66) | EDNRAEDNRBALDH1A1PGRTSHR | |
| SCHEMBL22034311 | 0.79 | NFE2L2 (0.46) | EDNRACCR4GAALMNASLC40A1 | |
| SCHEMBL22034314 | 0.79 | NFE2L2 (0.46) | EDNRACCR4GAALMNASLC40A1 | |
| SCHEMBL30634099 | 0.77 | CCR4 (0.55) | EDNRACCR4EDNRBLMNASLC40A1 | |
| SCHEMBL21048021 | 0.77 | CCR4 (0.55) | EDNRACCR4EDNRBLMNASLC40A1 | |
| SCHEMBL21047961 | 0.77 | CCR4 (0.64) | EDNRACCR4GAALMNA | |
| SCHEMBL30634098 | 0.77 | CCR4 (0.64) | EDNRACCR4GAALMNA | |
| SCHEMBL22088448 | 0.76 | EDNRA (0.56) | EDNRACCR4EDNRBGAALMNA | |
| SCHEMBL15758763 | 0.76 | POLB (0.51) | CCR4GAALMNAALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404248-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4201924-B1 | IRE1 SMALL MOLECULE INHIBITORS | UNIV CORNELL (US) | 2024-10-23 | — | — | EP | disclosed |
| US-20240287004-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2024-08-29 | — | — | US | disclosed |
| US-11945784-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2024-04-02 | — | — | US | disclosed |
| EP-3891130-B1 | IRE1 SMALL MOLECULE INHIBITORS | UNIV CORNELL (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-3891130-B1 | IRE1 SMALL MOLECULE INHIBITORS | UNIV CORNELL (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-4201924-A1 | IRE1 SMALL MOLECULE INHIBITORS | Cornell University (US) | 2023-06-28 | — | — | EP | disclosed |
| EP-4201924-A1 | IRE1 SMALL MOLECULE INHIBITORS | Cornell University (US) | 2023-06-28 | — | — | EP | disclosed |
| US-20220024878-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2022-01-27 | — | — | US | disclosed |
| EP-3891130-A1 | IRE1 SMALL MOLECULE INHIBITORS | Cornell University (US) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020117634-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020117634-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY (US) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11945784-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | EDNRA 2093/4885CCR4 3191/4885EDNRB 2191/4885 |
| US-20240287004-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | EDNRA 2093/4885CCR4 3191/4885EDNRB 2191/4885 |
| US-20220024878-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | EDNRA 2093/4885CCR4 3191/4885EDNRB 2191/4885 |
| US-12404248-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | EDNRA 2093/4885CCR4 3191/4885EDNRB 2191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.